Aura BiosciencesAURA
AURA
About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Employees: 106
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
160% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 15
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
16% more funds holding
Funds holding: 81 [Q3] → 94 (+13) [Q4]
4.67% more ownership
Funds ownership: 74.31% [Q3] → 78.98% (+4.67%) [Q4]
1% less capital invested
Capital invested by funds: $329M [Q3] → $324M (-$4.91M) [Q4]
94% less call options, than puts
Call options by funds: $16K | Put options by funds: $255K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
247%
upside
Avg. target
$22
301%
upside
High target
$25
356%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Citizens Capital Markets Jonathan Wolleben 44% 1-year accuracy 30 / 68 met price target | 247%upside $19 | Market Outperform Maintained | 26 Mar 2025 |
HC Wainwright & Co. Edward White 24% 1-year accuracy 35 / 148 met price target | 356%upside $25 | Buy Maintained | 25 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025.
Neutral
Seeking Alpha
1 month ago
Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)
Aura Biosciences, Inc (NASDAQ:AURA ) Virtual Urologic Oncology Investor Event Conference Call March 24, 2025 4:30 PM ET Company Participants Jill Hopkins - Chief Medical Officer & President of R&D Sabine Brookman-May - Senior Vice President, Therapeutic Area Head Urologic Oncology Joseph McQuaid - Clinical Lead, Urologic Oncology Jennifer Linehan - St. John's Cancer Institute Neal Shore - Carolina Urologic Research Center Gary Steinberg - Professor, Department of Urology at Rush University in Chicago Conference Call Participants Andy Berens - Leerink Philip Nadeau - TD Cowen Oliver McCammon - LifeSci Capital Jon Wolleben - JMP Securities George Farmer - Scotiabank Operator Good afternoon, and welcome to the Aura Biosciences Virtual Urologic Oncology Investor Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Aura website following the conclusion of the event.
Neutral
GlobeNewsWire
1 month ago
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential
Neutral
GlobeNewsWire
1 month ago
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect
Neutral
GlobeNewsWire
1 month ago
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) will be presented at the 40th Annual European Association of Urology (EAU) Congress being held March 21-24, 2025, in Madrid, Spain. Aura will also participate in the EAU Research Forum during the Congress.
Neutral
GlobeNewsWire
2 months ago
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
4 months ago
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Positive
Seeking Alpha
6 months ago
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer.
Positive
Benzinga
6 months ago
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC).
Neutral
GlobeNewsWire
6 months ago
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors
Charts implemented using Lightweight Charts™